People with obesity or type 2 diabetes who took a drug called tirzepatide lost a lot of weight—more when they took higher doses—and the effect lasted up to about three years.

People with obesity or type 2 diabetes who take tirzepatide are much more likely to lose a meaningful amount of weight—like 5%, 10%, or even 15% of their body weight—compared to those who don’t, and the more they take, the better the results seem to be.

In people with type 2 diabetes, the medication tirzepatide at 10 mg and 15 mg improves how the body responds to insulin more than can be explained by weight loss alone, suggesting other biological mechanisms are involved.

Over 36 months, tirzepatide lowered body weight and blood sugar levels more than dulaglutide in adults with type 2 diabetes and heart disease, while both drugs had similar effects on cardiovascular safety.

In adults who are overweight or obese but do not have diabetes, tirzepatide lowers both body mass index and blood sugar levels compared to other similar medications.

In people with type 2 diabetes, a weekly injection of tirzepatide at 10 mg or 15 mg is associated with better function of insulin-producing cells in the pancreas, shown by specific biomarker changes, compared to other treatments like dulaglutide or no active treatment.